K I Kaitin

Summary

Affiliation: Tufts University
Country: USA

Publications

  1. ncbi Translational research and the evolving landscape for biomedical innovation
    Kenneth I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Tufts University, Boston, MA 02111, USA
    J Investig Med 60:995-8. 2012
  2. ncbi Obstacles and opportunities in new drug development
    K I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts, USA
    Clin Pharmacol Ther 83:210-2. 2008
  3. ncbi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009
    K I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 89:183-8. 2011
  4. ncbi Impact of the new US health-care-reform legislation on the pharmaceutical industry: who are the real winners?
    C P Milne
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 88:589-92. 2010
  5. ncbi FDA review divisions: performance levels and the impact on drug sponsors
    C P Milne
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 91:393-404. 2012

Detail Information

Publications5

  1. ncbi Translational research and the evolving landscape for biomedical innovation
    Kenneth I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Tufts University, Boston, MA 02111, USA
    J Investig Med 60:995-8. 2012
    ..The goal for all stakeholders is to reduce the barriers to product development and bring new medicines to market in a timely and cost-efficient manner...
  2. ncbi Obstacles and opportunities in new drug development
    K I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Boston, Massachusetts, USA
    Clin Pharmacol Ther 83:210-2. 2008
  3. ncbi Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009
    K I Kaitin
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 89:183-8. 2011
    ..1 and 6.9 years, respectively). The results provide the underpinnings of a fundamental shift in the structure of the research-based industry...
  4. ncbi Impact of the new US health-care-reform legislation on the pharmaceutical industry: who are the real winners?
    C P Milne
    Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 88:589-92. 2010
    ....
  5. ncbi FDA review divisions: performance levels and the impact on drug sponsors
    C P Milne
    Tufts Center for the Study of Drug Development, Tufts University School of Medicine, Tufts University, Boston, Massachusetts, USA
    Clin Pharmacol Ther 91:393-404. 2012
    ....